Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 3/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.40 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873580 | 0.91 | CA1 (0.45) | CA2TP53CA1TSHRLMNA | |
| SCHEMBL9988552 | 0.91 | CA1 (0.45) | CA2TP53CA1TSHRLMNA | |
| SCHEMBL1834837 | 0.90 | MCHR1 (0.45) | CA2TP53CA1TSHRLMNA | |
| SCHEMBL1833804 | 0.90 | MCHR1 (0.45) | CA2TP53CA1TSHRLMNA | |
| SCHEMBL1836440 | 0.90 | MCHR1 (0.45) | CA2TP53CA1TSHRLMNA | |
| SCHEMBL19837798 | 0.86 | KAT2B (0.56) | CA2TP53CA1TSHRLMNA | |
| SCHEMBL7895152 | 0.86 | HRH1 (0.62) | HRH1SLC6A4SLC6A2SLC6A3HTR1A | |
| SCHEMBL28418035 | 0.83 | HTR1A (0.50) | HRH1SLC6A4SLC6A2SLC6A3KAT2B | |
| SCHEMBL19641661 | 0.79 | TP53 (0.47) | CA2TP53CA1TSHRLMNA | |
| SCHEMBL29186583 | 0.79 | KAT2B (0.47) | CA2TP53CA1TSHRKAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150376-A1 | Novel Sultam Compounds | PFIZER INC. (US) | 2013-06-13 | — | — | US | disclosed |
| EP-2556076-A2 | NOVEL SULTAM COMPOUNDS | Pfizer Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011125006-A2 | NOVEL SULTAM COMPOUNDS | PFIZER INC. (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150376-A1 | Novel Sultam Compounds | SULT2A1, SULT1A1, SULT1E1 | CA2 2009/4885TP53 3848/4885CA1 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.